GNI Group says it will be added to TOPIX from October 30, selected from the Tokyo Stock Exchange's Growth market in the first regular reshuffle since the index opened selection to all three market segments.
A ¥6.6bn reversal of Cullgen's preferred-share interest, not stronger drug sales, pushed GNI Group into the black for the first half, and the real growth test starts next quarter when Ayumi Pharmaceutical's revenue is added to the books.
The US registration covers Gyre shares issued in the Cullgen buyout, not fresh fundraising, and parent GNI says its effective interest stands at about 70 per cent with no material effect expected on consolidated results.
GNI plans to buy all of Ayumi Pharmaceutical Holdings for ¥44.776 billion and make it a wholly owned unit, arguing the deal adds a steadier Japanese earnings base plus an established sales network in rheumatology, orthopedics and fever-and-pain drugs. Ayumi reported revenue of ¥38.543 billion and operating profit of ¥6.206 billion in the year to March 2026, giving GNI a domestic commercial platform rather than just another pipeline promise. The financing is the real tell. GNI will pay ¥18.005 billion in cash and settle ¥26.771 billion through a contribution in kind, issuing 9,974,291 new shares to the sellers, while also lining up ¥20 billion of borrowing from Mizuho Bank and SBI Shinsei Bank. Management says the deal should close between June 30 and September 30, but existing holders face 17.89% share dilution and BCP is expected to emerge as the largest shareholder.
All articles loaded · 4 shown
5% holders
Latest disclosed holders and exits below 5%.
1 holder · data through
No stored data for this selection.
Exits below 5%
Exits below 5%
Holder
Stake
Change
Purpose
Filing
BCP Asia AYM Holding(Cayman)L.P.
4.97%
−5.64 pp
Pure investmentPure investmentOriginal (Japanese)純投資
Strategic shareholdings and sales, by fiscal year.
5 fiscal years · data through
Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.